ABOS
Price
$2.37
Change
-$0.00 (-0.00%)
Updated
Jun 12 closing price
Capitalization
171.18M
64 days until earnings call
Intraday BUY SELL Signals
ADAG
Price
$3.57
Change
-$0.01 (-0.28%)
Updated
Jun 12 closing price
Capitalization
235.88M
80 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABOS vs ADAG

Header iconABOS vs ADAG Comparison
Open Charts ABOS vs ADAGBanner chart's image
ABOS vs ADAG Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABOS vs. ADAG commentary
Jun 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and ADAG is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2026
Stock price -- (ABOS: $2.37 vs. ADAG: $3.57)
Brand notoriety: ABOS and ADAG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 127% vs. ADAG: 118%
Market capitalization -- ABOS: $171.18M vs. ADAG: $235.88M
ABOS [@Biotechnology] is valued at $171.18M. ADAG’s [@Biotechnology] market capitalization is $235.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $112.92B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileADAG’s FA Score has 0 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • ADAG’s FA Score: 0 green, 5 red.
According to our system of comparison, ADAG is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 5 TA indicator(s) are bullish while ADAG’s TA Score has 2 bullish TA indicator(s).

  • ABOS’s TA Score: 5 bullish, 4 bearish.
  • ADAG’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, ABOS is a better buy in the short-term than ADAG.

Price Growth

ABOS (@Biotechnology) experienced а +10.23% price change this week, while ADAG (@Biotechnology) price change was +7.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.78%. For the same industry, the average monthly price growth was +90.18%, and the average quarterly price growth was +2050.65%.

Reported Earning Dates

ABOS is expected to report earnings on Aug 17, 2026.

ADAG is expected to report earnings on Sep 02, 2026.

Industries' Descriptions

@Biotechnology (+0.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADAG($236M) has a higher market cap than ABOS($171M). ADAG YTD gains are higher at: 88.889 vs. ABOS (12.322). ADAG has higher annual earnings (EBITDA): -29.17M vs. ABOS (-108.82M). ABOS has more cash in the bank: 128M vs. ADAG (62.8M). ADAG has less debt than ABOS: ADAG (6.85M) vs ABOS (31.2M). ADAG has higher revenues than ABOS: ADAG (103K) vs ABOS (0).
ABOSADAGABOS / ADAG
Capitalization171M236M72%
EBITDA-108.82M-29.17M373%
Gain YTD12.32288.88914%
P/E RatioN/AN/A-
Revenue0103K-
Total Cash128M62.8M204%
Total Debt31.2M6.85M455%
TECHNICAL ANALYSIS
Technical Analysis
ABOSADAG
RSI
ODDS (%)
Bullish Trend 3 days ago
81%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
80%
Momentum
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 11 days ago
83%
Declines
ODDS (%)
Bearish Trend 11 days ago
87%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
85%
Aroon
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABOS
Daily Signal:
Gain/Loss:
ADAG
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCVAX10.450.12
+1.16%
Transamerica Mid Cap Value Opps A
MGLAX17.580.17
+0.98%
MFS Global Real Estate A
NBNRX15.920.14
+0.89%
Neuberger International Sel R3
GPEIX12.070.10
+0.84%
Grandeur Peak Emerg Mkts Opps Instl
EAASX29.700.15
+0.51%
Eaton Vance Atlanta Capital SMID-Cap A

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with CCXI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then CCXI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
N/A
CCXI - ABOS
48%
Loosely correlated
-0.68%
CELC - ABOS
44%
Loosely correlated
-1.05%
NKTX - ABOS
42%
Loosely correlated
+3.62%
RCKT - ABOS
39%
Loosely correlated
+3.38%
LXRX - ABOS
37%
Loosely correlated
+1.59%
More

ADAG and

Correlation & Price change

A.I.dvisor tells us that ADAG and QCLS have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ADAG and QCLS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAG
1D Price
Change %
ADAG100%
-0.28%
QCLS - ADAG
26%
Poorly correlated
+1.31%
ABOS - ADAG
25%
Poorly correlated
N/A
GERN - ADAG
24%
Poorly correlated
+0.88%
IBO - ADAG
23%
Poorly correlated
+4.46%
LENZ - ADAG
23%
Poorly correlated
+4.15%
More